Prevalence of the Central Vein Sign on Susceptibility-Weighted Imaging in People With Pediatric-Onset Multiple Sclerosis
Given the high sensitivity but only moderate specificity of current diagnostic criteria for multiple sclerosis (MS), novel diagnostic biomarkers for pediatric-onset MS (POMS) are highly warranted. The central vein sign (CVS) is a such promising MRI biomarker candidate that has been shown to distinguish MS from other neuroimmunologic diseases with high specificity. The aim of this study was to assess the prevalence of the CVS in POMS under real-world conditions by analyzing T2-hyperintense lesions using 1.5T susceptibility-weighted imaging (SWI).
Authors
- Frederik Bartels (ORCID: https://orcid.org/0000-0003-3523-4520)
- Kevin M. Rostasy (ORCID: https://orcid.org/0000-0002-2180-5321)
- Friedemann Paul (ORCID: https://orcid.org/0000-0002-6378-0070)
- Andreas Wegener-Panzer
- Robert Cleaveland
- Georgia Koukou (ORCID: https://orcid.org/0009-0003-1588-6633)
- Joseph Kuchling (ORCID: https://orcid.org/0000-0002-7981-2073)
- Ines El Naggar (ORCID: https://orcid.org/0000-0003-0685-0914)
- Carsten Finke (ORCID: https://orcid.org/0000-0002-7665-1171)
- Thomas Gowert
- Annikki Bertolini (ORCID: https://orcid.org/0000-0003-4196-022X)
Institutions
- Witten/Herdecke University (DE)
- Max Delbrück Center (DE)
- Humboldt-Universität zu Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology Open Access
- Published
- 2025-08-04
- DOI
- https://doi.org/10.1212/wn9.0000000000000031
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Sanofi
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Sanofi Genzyme
- UCB Pharma